FHFatin Syakirah Halim

Fatin Syakirah Halim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fatin Syakirah Halim has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Designing DNA probe from HPV 18 and 58 in the E6 region for sensing element in the development of genosensor‐based gold nanoparticles

    by F. Nadhirah Jaapar, N.A. Parmin, N. Hamidah A Halim, Uda Hashim, Subash C.B. Gopinath, F. Syakirah Halim, A. Rahim Ruslinda, C.H. Voon, M.N. Afnan Uda, Sh. Nadzirah, et al.

    E6 region has higher protuberant probability annealing than consensus probe focusing on another region in Human Papillomavirus (HPV) genome in terms of detection and screening method. Here, we designed the first multiple virus ssDNA for multiple detections in an early phase of screening for cervical cancer in the E6 region and became a fundamental evolution of detection electrochemical HPV biosensor. Gene profiling of the virus ssDNA sequences have been carried by high-end bioinformatics tools such as GenBank, Basic Local Alignment Searching Tools (BLAST), and Clustal OMEGA in a row. The output from bioinformatics tools resulted in 100% of similarities between our virus ssDNA probe and HPV complete genome in the databases. The cross-validation between HPV genome and our designed virus ssDNA provided high specificity and selectivity during screening methods compared with Pap smear. The DNA probe for HPV 18, 5' COOH-GAT CCA GAA GGT ACA GAC GGG GAG GGC ACG 3' while 5'COOH-GGG CGC TGT GCA GTG TGT TGG AGA CCC CGA3' as DNA probe for HPV 58 designed with 66.77% Guanine (G) and Cytosine (C) content for both. Our virus ssDNA probe for HPV biosensor promising high sensitivity, specificity, selectivity, repeatability, low fluid consumption, and mini-size diagnostic devices. Bioinformatics tools such as GenBank, Basic Local Alignment Searching Tools (BLAST), and Clustal OMEGA assist in analyzing and designing 30-mer of virus ssDNA as a probe in this study. Virus ssDNA probes prove higher selectivity, sensitivity, and specificity on different target sequences for HPV 16, 18, and 58. Surface modification via nanotechnology self-assemble layer of gold-nanoparticles (AuNPs) on large volume to ratio Interdigitated Electrodes (IDE) for developing HPV biosensor (future work). This article is protected by copyright. All rights reserved


  • Open Access

    MicroRNA of N‐region from SARS‐CoV‐2: Potential sensing components for biosensor development

    by Fatin Syakirah Halim, N. A. Parmin, Uda Hashim, Subash C.B. Gopinath, Farrah Aini Dahalan, Iffah Izzati Zakaria, Wei Chern Ang, Nurfareezah Fareezah Jaapar

    An oligonucleotide DNA probe has been developed for the application in the DNA electrochemical biosensor for the early diagnosis of coronavirus disease (COVID‐19). Here, the virus microRNA from the N‐gene of severe acute respiratory syndrome‐2 (SARS‐CoV‐2) was used for the first time as a specific target for detecting the virus and became a framework for developing the complementary DNA probe. The sequence analysis of the virus microRNA was carried out using bioinformatics tools including basic local alignment search tools, multiple sequence alignment from CLUSTLW, microRNA database (miRbase), microRNA target database, and gene analysis. Cross‐validation of distinct strains of coronavirus and human microRNA sequences was completed to validate the percentage of identical and consent regions. The percent identity parameter from the bioinformatics tools revealed the virus microRNAs’ sequence has a 100% match with the genome of SARS‐CoV‐2 compared with other coronavirus strains, hence improving the selectivity of the complementary DNA probe. The 30 mer with 53.0% GC content of complementary DNA probe 5′ GCC TGA GTT GAG TCA GCA CTG CTC ATG GAT 3′ was designed and could be used as a bioreceptor for the biosensor development in the clinical and environmental diagnosis of COVID‐19.